Role of prevention and screening in epithelial ovarian cancer
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20150404Keywords:
Screening, Transvaginal ultrasound, CA-125, Risk reducing surgeryAbstract
Epithelial ovarian carcinoma is a disease with poor prognosis and high mortality among gynaecological cancers due to inaccessibility of ovary for inspection or sampling and lack of proper screening methods. Strategies to detect early ovarian cancer include estimation of serum CA-125 and transvaginal ultrasound (TVS) for morphological index. Studies have shown that screening of asymptomatic average risk post-menopausal women did not show any benefit and are associated with false positive results which may lead to unnecessary surgery and resultant morbidity. The risks outweigh benefits.
Present recommendation is to screen high risk women especially hereditary cancers and offer risk reducing surgery when needed. Prophylactic salpingectomy/oophorectomy may offer the opportunity to prevent ovarian cancer. More trials and more research in newer biomarkers are needed.
Metrics
References
American cancer society, Cancer facts and figures 2011. Atlanta, GA; American Cancer Society:2011
National Cancer Institute. SEER stat fact sheets Ovary, Bethesda, MD; National Cancer Institute:2011.
Parkin DM, Whelan SL, Ferlay J et al.(eds). Cancer incidence in Five Continents, Vol VIII, International Agency for Research in Cancer, Lyon, France, IARC Publication No:155, 2002.
National Cancer Registry Programme, Indian Council of Medical Research, Two year report of population based Cancer Registries, 2004-5, Incidence and distribution of Cancer, Bangalore, India, 2008.
Daniilidas A, Karagiannis V. Epithelial ovarian cancer risk factors, screening and role of Prophylactic oophorectomy. Hippokratia.s 2007;11:63-6.
Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA mutation carriers, Breast cancer linkage consortium. Am J Hum Genet. 1995;56:265-71.
Johnathan M, Lancaster C, Bethan P, Noah D et al. Statement on risk assessment for inherited gynaecologic cancer predisposition. Gynecologic Oncology. 2007;107:159-62.
Chen S, Parmigiani G. Meta-analysis of BRCA-1 and BRCS-2 penetrance. J Clin Oncol. 2007;25:1329-33.
Rizzuto I, Behrens RF, Smith LA. Risk of ovarian cancer in women treated with ovarian stimulating drugs for infertility. Cochrane Data Base Syst Rev 2013;8:CD008215.
Permuth-wey J, Sellars TA. Epidemiology of ovarian cancer-Methods of molecular biology. Cancer epidemiology. 2009;472:413-7.
The American College of Obstetricians and Gynecologists Committee Opinion, The Role of the Obstetrician-Gynecologist in the early detection of Epithelial Ovarian Cancer. Obstet Gynecol 2011;117:742-6.
Carlson KJ, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med 1994; 121: 124-32.
Geomini P, Kruit Wagen R, Bremer GI et al. The accuracy of risk factors in predicting ovarian malignancy, A systematic review. Obstet Gynecol 2009; 113:384-94.
Timmerman D, Valentin L, Bourne TH et al. International Ovarian Tumor analysis (TOTA) group terms, definitions and measurements to describe the sonographic features of adnexal tumors, A consensus opinion from International ovarian tumor analysis group. Ultrasound Obstet & Gynecol. 2000;16:500-5.
ACOG practical bulletin No.83, Management of adnexal masses. Obstet Gynecol. 2007;110:201-14.
Cramer DW, Bast RC Jr, Berg CD et al. Ovarian cancer biomarker performance In prostate, lung, colorectal, ovarian cancer screening trial specmens. Cancer Prev.Res(Phila). 2011;4(3):365-74.
Moore LE, Pfeiffer RM, Zhang Z et al. Protemic biomarkers in combination with CA-125 for detection of epithelial ovarian cancer using pre-diagnostic serum samples from prostate, lung, colorectal, ovarian (PLCO) cancer screening trial. Cancer 2012;118(1):91-100.
Yushen Cheng, Chongdong Liv, Naweizhang et al.Proteomics analysis for finding serum markers of ovarian cancer. Biomed Research International. 2014, Article ID:179040
Bast RC Jr, Brewer M, Zou C, Hernandez MA et al. Preventive and early detection of ovarian carcinoma: mission Impossible? Recent Results Cancer Res. 2007;174:91-100.
US Preventive services Task force, Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility. Ann Intern Med 2005;143:355-61.
Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: The prostate, lung, colorectal and ovarian (PLCO) cancer screening, Randomised controlled trial. JAMA. 2011;305:2295-303.
Danforth KN, Theresa M, Whitelock EP. Addendum to screening for ovarian cancer: Evidence update for the US Preventive services task force reaffirmation recommendation statement. AHRQ Publication No:12-05165-EF4 April 2012.
Menon V, Gentry-Maharaj A, Hallet et al. Sensitivity ansd specificity of multimodal and ultrasound screening for ovarian cancer and stage distribution of detected cancers-Results of the prevalence of the UK collaborative trial of Ovarian cancer screening (UKCTOCS) Lancet Oncol. 2009;10(4):327-40.
Rebbeck TR, Lynch HT, Neuhausen SL et al. Prophylactic oophorectomy in BRCA-1 or BRCA-2 mutations. N Eng J Med. 2002;346:1616-22.
EveMaria GG, Thomas Anthony W. Risk reducing surgey for women at high risk of epithelial ovarian cancer. The Obstetrician and Gynaecologist. 2014;16:185-91.
Carlson JW, Miran A, Jarboe EA et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J ClinOncol 2008; 26:4160-5.
Kwon JS, Tinker A, Pansegrau G et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013;121:14-24.
RCOG- The distal fallopian tube as the origin of non-uterine pelvic high grade serous carcinomas. Scientific impact paper N0:44, Nov 2014 :2-8.
